Human c-SRC kinase (CSK) overexpression makes T cells dummy
- 551 Downloads
Adoptive cell therapy with T-cell receptor (TCR)-engineered T cells represents a powerful method to redirect the immune system against tumours. However, although TCR recognition is restricted to a specific peptide–MHC (pMHC) complex, increasing numbers of reports have shown cross-reactivity and off-target effects with severe consequences for the patients. This demands further development of strategies to validate TCR safety prior to clinical use. We reasoned that the desired TCR signalling depends on correct pMHC recognition on the outside and a restricted clustering on the inside of the cell. Since the majority of the adverse events are due to TCR recognition of the wrong target, we tested if blocking the signalling would affect the binding. By over-expressing the c-SRC kinase (CSK), a negative regulator of LCK, in redirected T cells, we showed that peripheral blood T cells inhibited anti-CD3/anti-CD28-induced phosphorylation of ERK, whereas TCR proximal signalling was not affected. Similarly, overexpression of CSK together with a therapeutic TCR prevented pMHC-induced ERK phosphorylation. Downstream effector functions were also almost completely blocked, including pMHC-induced IL-2 release, degranulation and, most importantly, target cell killing. The lack of effector functions contrasted with the unaffected TCR expression, pMHC recognition, and membrane exchange activity (trogocytosis). Therefore, co-expression of CSK with a therapeutic TCR did not compromise target recognition and binding, but rendered T cells incapable of executing their effector functions. Consequently, we named these redirected T cells “dummy T cells” and propose to use them for safety validation of new TCRs prior to therapy.
KeywordsT-cell receptor TCR TCR signalling CSK Immunotherapy
Antigen presenting cells
Fetal calf serum
Green fluorescent protein
Good manufacturing practice
Immunoreceptor tyrosine-based activation motifs
Melanoma-associated antigen 3
Melanoma antigen recognized by T cells 1
Mean fluorescence intensity
Peripheral blood mononuclear cells
Transforming growth factor β II
The authors would like to thank the members of the Smeland lab and of the Department of Cellular Therapy for their positive input and support. We are also thankful to Dr. Pierre Dillard for commenting on this manuscript.
EMI, SW, GES, LEF, and JHM conceived and designed the experiments. EMI, NM, MPO, AF, GS, CP, and JHM performed the experiments. SW, OB, GK, and JHM interpreted the data. SW, EMI, NM, and JHM wrote the manuscript and all authors edited the manuscript.
This work was supported by the Gene Therapy program of the Radium Hospital to Sébastien Wälchli and Anne Fåne, The Norwegian Research Council to Else Marit Inderberg (#244388), and partly supported by an Innovation Grant from Southern and Eastern Norway Regional Health Authority to Nadia Mensali (#13/00367-88).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was approved by the Regional Committee for Medical and Health Research Ethics (REC South-East, Norway) (Approval no. 2013/624).
Informed consent from healthy donors was given.
- 3.Malissen B, Bongrand P (2015) Early T cell activation: integrating biochemical, structural, and biophysical cues. Annu Rev Immunol 33:539–561. https://doi.org/10.1146/annurev-immunol-032414-112158 CrossRefPubMedGoogle Scholar
- 8.Vang T, Liu WH, Delacroix L, Wu S, Vasile S, Dahl R, Yang L, Musumeci L, Francis D, Landskron J, Tasken K, Tremblay ML, Lie BA, Page R, Mustelin T, Rahmouni S, Rickert RC, Tautz L (2012) LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 8(5):437–446. https://doi.org/10.1038/nchembio.916 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, Clever D, Chichura A, Roychoudhuri R, Varma R, Wang E, Gattinoni L, Marincola FM, Balagopalan L, Samelson LE, Restifo NP (2015) Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med 212(12):2095–2113. https://doi.org/10.1084/jem.20150304 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R (2008) Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 14(8):2484–2491. https://doi.org/10.1158/1078-0432.CCR-07-4393 CrossRefPubMedGoogle Scholar
- 15.Okoye I, Wang L, Pallmer K, Richter K, Ichimura T, Haas R, Crouse J, Choi O, Heathcote D, Lovo E, Mauro C, Abdi R, Oxenius A, Rutschmann S, Ashton-Rickardt PG (2015) T cell metabolism. The protein LEM promotes CD8(+) T cell immunity through effects on mitochondrial respiration. Science 348(6238):995–1001. https://doi.org/10.1126/science.aaa7516 CrossRefPubMedGoogle Scholar
- 16.Ebert PJR, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA, Kim JM, Belvin M, Mellman I (2016) MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44(3):609–621. https://doi.org/10.1016/j.immuni.2016.01.024 CrossRefPubMedGoogle Scholar
- 17.Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP (2016) Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537(7621):539–543. https://doi.org/10.1038/nature19364 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Vang T, Abrahamsen H, Myklebust S, Enserink J, Prydz H, Mustelin T, Amarzguioui M, Tasken K (2004) Knockdown of C-terminal Src kinase by siRNA-mediated RNA interference augments T cell receptor signaling in mature T cells. Eur J Immunol 34(8):2191–2199. https://doi.org/10.1002/eji.200425036 CrossRefPubMedGoogle Scholar
- 22.Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy E, Willemze R, Falkenburg JH (2003) Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102(10):3530–3540CrossRefPubMedGoogle Scholar
- 23.Walchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF (2014) Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation. Eur J Immunol 44(3):774–784. https://doi.org/10.1002/eji.201343671 CrossRefPubMedGoogle Scholar
- 25.Inderberg EM, Walchli S, Myhre MR, Trachsel S, Almasbak H, Kvalheim G, Gaudernack G (2017) T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth. Oncoimmunology 6(4):e1302631. https://doi.org/10.1080/2162402X.2017.1302631 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R (2013) High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 121(8):1367–1376. https://doi.org/10.1182/blood-2012-04-421826 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 177(9):6548–6559CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R, van den Berg HA, Gostick E, Gallagher K, Jones E, Melenhorst JJ, Godkin AJ, Peakman M, Price DA, Sewell AK, Wooldridge L (2009) Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 340(1):11–24. https://doi.org/10.1016/j.jim.2008.09.014 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Wolchinsky R, Hod-Marco M, Oved K, Shen-Orr SS, Bendall SC, Nolan GP, Reiter Y (2014) Antigen-dependent integration of opposing proximal TCR-signaling cascades determines the functional fate of T lymphocytes. J Immunol 192(5):2109–2119. https://doi.org/10.4049/jimmunol.1301142 CrossRefPubMedGoogle Scholar
- 40.Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, Gomez-Eerland R, Thome M, Schumacher TN, Romero P, Speiser DE, Zoete V, Michielin O, Rufer N Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184(9):4936–4946Google Scholar
- 41.Nika K, Soldani C, Salek M, Paster W, Gray A, Etzensperger R, Fugger L, Polzella P, Cerundolo V, Dushek O, Hofer T, Viola A, Acuto O (2010) Constitutively active Lck kinase in T cells drives antigen receptor signal transduction. Immunity 32(6):766–777. https://doi.org/10.1016/j.immuni.2010.05.011 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6):863–871. https://doi.org/10.1182/blood-2013-03-490565 CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK (2013) Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 5(197):197ra103. https://doi.org/10.1126/scitranslmed.3006034 CrossRefPubMedGoogle Scholar
- 45.Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci USA 106(29):12073–12078. https://doi.org/10.1073/pnas.0903852106 CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S (2015) CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29(8):1637–1647. https://doi.org/10.1038/leu.2015.52 CrossRefPubMedPubMedCentralGoogle Scholar